AOBO 001

Drug Profile

AOBO 001

Alternative Names: AOBO-001; Cease Enuresis Soft Gel

Latest Information Update: 05 Aug 2015

Price : $50

At a glance

  • Originator American Oriental Bioengineering
  • Class Herbal medicines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Urinary incontinence
  • Discontinued Overactive bladder

Most Recent Events

  • 15 Nov 2011 American Oriental Bioengineering completes a phase II trial in Overactive bladder in US (NCT01294982)
  • 22 Jul 2011 American Oriental Bioengineering completes enrolment in its phase II trial for Overactive bladder in USA (NCT01294982)
  • 31 Dec 2010 Phase-II clinical trials in Overactive bladder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top